Weight loss drugs, which took the US market by storm, are looking to be a big opportunity for drug makers in India. Several ...

We expect Novo to gain $75 billion of a more than $200 billion global GLP-1 market in diabetes and obesity by 2031, ahead of semaglutide's 2032 patent expiration, with Lilly standing as the firm's key ...

Novo Nordisk today announced 2024 earnings, reporting a 26% increase in annual sales to ~$40.56bn. Read why I upgrade NVO ...

Taking a compounded GLP-1 medication isn’t the same thing as your pharmacy filling a cheaper, generic version of the drug ...

Rybelsus (semaglutide) is a brand-name prescription medication that ... Factors such as whether a drug is a brand name or generic contribute to the tier. A drug’s tier determines a person’s copayment ...

Ozempic, the drug that was originally approved to treat type 2 diabetes, has now also been approved by the FDA to reduce ...

In recent years, the pharmaceutical industry has undergone significant changes in the focus of its innovation, research and ...

THESE MEDICATIONS ARE MOSTLY KNOWN FOR TREATING DIABETES AND OBESITY.. BUT THE F-D-A HAS APPROVED THEM FOR PREVENTING HEART ...

Weight loss medications like Ozempic and Wegovy have become increasingly popular over the last few years. For people struggling to lose weight through diet and exercise alone, these medications ...

“So, I am pre-diabetic. And I am on semaglutide.” Semaglutide is the generic form of the drug Ozempic, according to the University of California Davis. It was approved in 2017 by the U.S. Food ...

Lots of people are on cheaper compounded weight-loss drugs that mimic brands like Ozempic, Wegovy, and Zepbound. They're about to lose access.